Scorpion Biological Services, a US-based biopharmaceutical contract development and manufacturing organisation (CDMO) and contract research organisation (CRO), announced on Tuesday that it has named Stephan Kutzer, PhD as its interim chief executive officer.

Presently, Dr Kutzer serves on the company's advisory board. He has over 25 years of experience in the pharmaceutical and biotech industries, managing successful contract development and manufacturing organisations. He has held the position of president and chief executive officer of Alcami Corporation and president, divisional CEO and chief operating officer of the Pharma Biotech & Customer Manufacturing division of Lonza Group AG. He has served as a member of the Executive Management Board of Lonza Group AG; president of Lonza Biologics Inc; chairman of the board of directors of Lonza Singapore Inc; chairman of the board of directors of Teva-Lonza TL Biopharmaceuticals AG; chairman of the board of directors of Lonza Biologics plc.; and president and chairman of Lonza Inc. He has also held the position of executive director on the board of directors for the Drug, Chemical & Associated Technologies Association (DCAT).

David Halverson, Scorpion Biological Services president, said: "With the rapid growth of Scorpion and the announcement of our new commercial-scale biomanufacturing facility in Manhattan, Kansas, Scorpion welcomes Stephan to this position. We look forward to advancing into our next phase of growth under his stewardship."